DOCSLIB.ORG

Valeant: an Enduring Engine for Growth

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Valeant: an Enduring Engine for Growth Valeant: An Enduring Engine for Growth December 16, 2015 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding guidance with respect to expected revenues, non-GAAP cash earnings per share, adjusted cash flows from operations and organic product sales growth, future disclosures, launches and approvals of products, business development activities, and the 2016 strategic initiatives of Valeant Pharmaceuticals International, Inc. (the “Company”). Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “seeks,” “potential,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management, and depend on assumptions, data or methods that may be incorrect or imprecise and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes. Note 1: The guidance in this presentation is only effective as of the date given, December 15, 2015, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. 1 <portrait> J. Michael Pearson Chairman and CEO 2 Drivers of Valeant’s success Our collection of great healthcare brands around the world Our relentless focus on providing easy and affordable access for physicians and patients Our innovative strategies (often disruptive), which have challenged industry convention Our exceptionally productive approach to R&D Our decentralized model and talented people, which give us a competitive edge (speed of decision making and in- depth customer knowledge) 3 A collection of great brands in a breadth of therapeutic areas Valeant 2016 forecast revenues Total: $12.5 – 12.7 B Oncology, Dentistry, Women’s Health, 17% Dermatology and Neuro and Other 22% Skin Care 22% Emerging markets (including 19% Ophthalmology and Ophthalmology, Eye Care (B+L) Dermatology, and GI sales) 21% Gastrointestinal (GI) 4 Dermatology ▪ Great brands in attractive segments ▪ Importance of trust-based physician relationships ▪ Concentrated, specialist prescriber base ▪ Attractive from a payor standpoint – High component of cash pay – Reasonably priced products ▪ Lower-cost, lower risk R&D 4-year mkt CAGR: ~5% 5 Ophthalmology (B+L) ▪ Strong underlying global growth drivers (e.g., demographics) ▪ Attractive specialty Rx and OTC segments ▪ Importance of trust-based physician relationships ▪ Concentrated, specialist prescriber base ▪ Significant unmet medical needs ▪ Opportunity for lower-risk innovation ▪ Low exposure to reimbursement pressure; significant cash pay ▪ Durable products 4-year mkt CAGR: ~6% 6 Gastrointestinal ▪ Concentrated, specialist prescriber population ▪ Importance of trust-based physician relationships ▪ Concentrated, specialist prescriber base ▪ Less of a priority for many larger pharma companies ▪ Favorable reimbursement ▪ Opportunity for low-risk, incremental innovation 7 Emerging markets ▪ 1,000+ brands with sales in emerging markets ▪ High growth markets (e.g., Mexico, China, Middle East / North Africa) ▪ Rich pipeline of upcoming launches ▪ Decentralized operating model ▪ Products not dependent on reimbursement ▪ Local R&D capabilities 4-year mkt CAGR: ~7% 8 Valeant Access Program with Walgreens – Physician/Pharmacist/Patient-led experience ▪ Direct distribution to patients through Walgreens Branded Access Program ▪ All products in Walgreens on consignment; Walgreens never takes title ▪ Walgreens paid a distribution and pharmacy fulfillment fee Branded Generic ▪ Valeant sets prices to the patient Access Program ▪ Ensures affordable, immediate access to all Valeant brands in program that physicians prescribe (for eligible patients) 9 Our innovative strategies – the early years 2008 2009 2010 Then ▪ Dramatically ▪ Began building ▪ Executed ▪ ~$600M in revenue reduced OPEX undervalued merger of (e.g., to focus BGx and OTC equals with ▪ 8% operating margin predominantly on businesses Biovail (strong and 1% growth customer-facing (e.g., in strategic fit, areas) emerging improved tax markets) rate) ▪ Imminent Effudex generics ▪ Shifted from high- risk/high-spend ▪ Initiated new ▪ Bloated cost base and R&D (e.g. R&D capability infrastructure neurology, and operating virology) to lower model (e.g., cost “singles and Dow) ▪ High risk, high spend R&D doubles” ▪ Demotivated organization ▪ Built unrivaled M&A capabilities (e.g., requiring returns in excess of cost of capital) 10 Our innovative strategies – recent years 2011 2013 2015 /12 /14 Now ▪ Built a leading ▪ Gained critical ▪ Secured entry into US market mass in attractive GI space with ▪ $12.5-12.7B in revenue position in ophthalmology acquisition of Salix dermatology, with acquisition ▪ Double-digit organic with a series of B+L ▪ Created even better, growth of focused branded access acquisitions ▪ New R&D model program with Walgreens (e.g., Medicis, beginning to ▪ Great brands around Obagi, pay dividends ▪ Launched with the world Dermik/Ortho) Walgreens the first ▪ Created branded generics ▪ Attractive geographies attractive program in the US and TA platforms access program in dermatology initially through ▪ Energized and partnership with committed talent base Philidor 11 Our R&D model ▪ 6 NDAs approved in last 3 years ▪ 200+ active US programs Rx R&D spend as a % of 8% branded Rx ▪ Dermatology Phase II and sales Phase III success rates 3-5x better than industry averages ▪ Highest 5 year output1 on R&D spend in the industry 1 Number of NMEs/BLAs approved 2009-'14 for each $1 billion spent; peer set is 15 companies with the highest number of NME/BLA approvals 12 Our decentralized model ▪ Empowers local leaders to make decisions that are right for their business ▪ Allows us to move with speed and agility ▪ Aligns with our customers’ needs ▪ Ensures strong centralization and controls in key functions/ activities, e.g., – Finance – Compliance – Audit – Pharmacovigilance 13 How you can measure our progress in 2016 ▪ Retained all key management talent and added new key hires ▪ Dermatology returned to growth ▪ Maximized Xifaxan – created our first $1B brand ▪ Got approval and successfully launched – Brodalumab – Latanoprostene Bunod – Relistor Oral ▪ Delivered $100-150M in addyi sales in 2016 ▪ Brought leverage to ~4.0x by end of 2016 14 Who you will hear from – Our business leaders Robert Rosiello Deb Jorn Tracy Valorie EVP, CFO EVP, Dermatology and GI SVP and GM, Women’s Health and Bausch + Lomb Pharmaceutical Division Mark McKenna Yang Yang Joe Gordon VP and GM, BU Director, SVP and GM, Bausch + Lomb Vision Care China & Japan Consumer Health Care Fernando Zarate Dr. Tage Ramakrishna GM, Mexico, Andean region, Chief Medical Officer, Head of Central America and R&D and Quality Caribbean 15 Financial guidance <portrait> Robert Rosiello Executive VP, CFO 16 Revised Q4 2015 and full-year 2015 guidance Previous Q4 Revised Q4 2015 2015 Guidance Guidance Revenue ~$3.25 - $3.45B ~$2.7 - $2.8B Adjusted EPS* ~$4.00 - $4.20 ~$2.55 - $2.65 per share per share Adj. Cash >$1.0B >$600M Flow from Operations* * Non-GAAP (see Appendix) 17 Bridge from previous Q4 2015 guidance Adjusted Revenue EPS* Midpoint of previous guidance ~$3,350M ~$4.10 Philidor separation ~($250M) ~($0.65) Estimated one-time revenue impact from ~($150M) ~($0.40) Walgreens transition Pricing and volume-related changes (e.g., non- ~($200M) ~($0.45) promoted products) Midpoint of revised guidance ~$2,750M ~$2.60 * Non-GAAP (see Appendix) 18 Philidor separation . Announced Philidor separation October 30 . Provided free scripts from October 31 to November 8 . Dispensed refills without seeking reimbursement from payors from November 9 to present . Average cash pay price declined from $67 to $23 . Lost ~20% of scripts from business disruption in Q4, virtually all Philidor covered scripts Estimated Q4 Revenue Impact: (~$250M) 19 One-time revenue impact from Walgreens transition . Transition to consignment model at Walgreens for current inventory on hand Under this arrangement, Valeant will hold title to products sold under this program until dispensed to a patient Valeant will credit Walgreens for any inventory on hand in its stores or distribution centers as part of transition . Estimated reduction in traditional channel inventories for the products included in Walgreens program 20 2016 guidance 2016 Guidance Revenue ~$12.5B – 12.7B Adj. EPS* ~$13.25 – 13.75 per share Adj. EBITDA* ~$6.9 – 7.1B * Non-GAAP (see Appendix) 21 Bridge from previous 2016 EBITDA outlook Previous 2016 Adj. EBITDA* Outlook >$7.50B Dermatology Patient Access Program ramp-up ~($225M) Changes
Load more

Recommended publications
  • Snippet Roundup: CETP Kaput and Biogen Buys Into Amyloid
    October 27, 2017 Snippet roundup: CETP kaput and Biogen buys into amyloid Edwin Elmhirst Welcome to your weekly roundup of EP Vantage’s snippets – short takes on smaller news items. This week, October 23 to 27, 2017, we had thoughts on the following: Amgen puts another CETP out of its misery; Stryker buys Vexim without waiting for US approval; How much is aducanumab worth? At least $8bn, Biogen reckons; Alcon delay puts dampener on Novartis; Soliris sitting pretty with complementary new indication; Smith & Nephew acquires, but divestments could follow; Global Blood drops IPF programme. These snippets were previously published daily via twitter. Amgen puts another CETP out of its misery October 26, 2017 If the once-promising CETP drug class lives on, it might only be in a rather restricted group of heart disease patients with a very specific mutation. Amgen became the last big biopharma group to cancel work on a drug in the HDL-raising class when it announced plans to seek a partner for AMG 899, following the lead of Merck & Co, which recently terminated its work with anacetrapib after disappointing results in the Reveal trial. Although big pharma groups obviously believe that it is unlikely for a CETP inhibitor to succeed commercially, it is not out of the realm of possibility that a partner could emerge for AMG 899 – Roche licensed its project, dalcetrapib, to the Canadian group Dalcor Pharmaceuticals, which has been researching its use in a genetic subtype, patients with an AA polymorphism at the rs1967309 location in the ADCY9 gene. Amgen will write off the $300m it paid for AMG 899’s originator, Dezima Pharma, in 2015, which at the time was seen as a cheap bet on the CETP sector.
    [Show full text]
  • Abbvie Allergan Acquisition
    Creating a New Diversified Biopharmaceutical Company The Combination of AbbVie and Allergan Investor Presentation June 25, 2019 NO OFFER OR SOLICITATION This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this presentation is not an offer of securities for sale into the United States. No offer of securities shall be made in the United States absent registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. Any securities issued in the acquisition are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act of 1933, as amended. The acquisition will be made solely by means of the Scheme Document (or, if applicable, the Takeover Offer document), which will contain the full terms and conditions of the acquisition, including details with respect to the AbbVie shareholder vote in respect of the acquisition. Any decision in respect of, or other response to, the acquisition, should be made only on the basis of the information contained in the Scheme Document. IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC In connection with the proposed Acquisition, Allergan will file with the Securities Exchange Commission (the “SEC”) a Proxy Statement, which will include the Scheme Document.
    [Show full text]
  • [Docket No. FDA-2017-N-3203] Wyeth Pharmaceutical
    This document is scheduled to be published in the Federal Register on 06/21/2017 and available online at https://federalregister.gov/d/2017-12908, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-N-3203] Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 121 new drug applications (NDAs) and 161 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. DATES: The withdrawal is effective on [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601. SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. 2 Table 1 Application No.
    [Show full text]
  • Print Layout 1
    TECHNICAL PROGRAM Monday, March 19 5:00 – 8:00 pm Welcome Reception Tuesday, March 20 8:00 – 10:00 Session 1: Setting the Conference Context and Drivers Chair: Geoff Slaff (Amgen) Roger Perlmutter (Amgen) Conquering the Innovation Deficit in Drug Discovery Helen Winkle (CDER, FDA) Regulatory Modernization 10:00 – 10:30 Break Vendor and poster review 10:30 – 12:30 Session 2: Rapid Cell Line Development and Improved Expression System Development Chairs: Timothy Charlebois (Wyeth) and John Joly (Genentech) Amy Shen (Genentech) Stable Antibody Production Cell-Line Development with an Improved Selection Process and Accelerated Timeline Mark Leonard (Wyeth) High-Performing Cell-Line Development within a Rapid and Integrated Platform Process Control Pranhitha Reddy (Amgen) Applying Quality-by-Design to Cell Line Development Lin Zhang (Pfizer) Development of a Fully-Integrated Automated System for High-Throughput Screening and Selection of Single Cells Expressing Monoclonal Antibodies 12:30 – 2:00 Lunch Vendor and poster review 2:00 – 4:30 Session 3: High-Throughput Bulk Process Development Chairs: Brian Kelley (Wyeth) and Jorg Thommes (Biogen Idec) Colette Ranucci (Merck) Development of a Multi-Well Plate System for High-Throughput Process Development Min Zhang (SAFC Biosciences) CHO Media Library – an Efficient Platform for Rapid Development and Optimization of Cell Culture Media Supporting High Production of Pharmaceutical Proteins in Chinese Hamster Ovary Cells Nigel Titchener-Hooker The Use of Ultra-Scale-Down Approaches to Enable Rapid Investigation
    [Show full text]
  • Pfizer and Mylan Will Own 57% and 43% of the New Company (“Newco”), Respectively
    DEAL PROFILE PFIZER | MYLAN VALUES 57% 43% $12.0bn PFIZER SHARE OF NEWCO MYLAN SHARE OF NEWCO NEW DEBT RAISED Pfizer Inc. (NYSE:PFE) Pfizer Inc. (“Pfizer”) is a pharmaceutical company that develops, manufactures, and sells products in internal medicine, vaccines, oncology, inflammation & immunology, and rare diseases. Upjohn, a subsidiary of Pfizer, is composed of Pfizer’s oral solid generics and off-patent drugs franchise, such as Viagra, Lipitor, and Xanax. Upjohn has a strong focus in emerging markets, and is headquartered in Shanghai, China. TEV: $265.4bn LTM EBITDA: $22.5bn LTM Revenue: $55.7bn Mylan N.V. (NASDAQ:MYL) Mylan N.V. (“Mylan”) is a pharmaceutical company that develops, manufactures, and commercializes generic, branded-generic, brand-name, and over-the-counter products. The company focuses in the following therapeutic areas: cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women’s health. Mylan was founded in 1961 and is headquartered in Canonsburg, PA. TEV: $23.9bn LTM EBITDA: $3.5bn LTM Revenue: $11.3bn Bourne Partners provides strategic and financial advisory services to BOURNE clients throughout the business evolution life cycle. In order to provide PARTNERS the highest level of service, we routinely analyze relevant industry MARKET trends and transactions. These materials are available to our clients and partners and provide detailed insight into the pharma, pharma services, RESEARCH OTC, consumer health, and biotechnology sectors. On July 29, 2019, Pfizer announced the spin-off of its off-patent drug unit, Upjohn, in order to merge the unit with generic drug manufacturer, Mylan.
    [Show full text]
  • Q1 Pharma Sector Snapshot
    SPECIALTY & GENERIC PHARMA Q1 2021 Report Market Commentary – Debt Capital Markets Debt Markets ▪ 2020 saw increased amounts of debt used in buyouts across the board, resulting in the highest debt / EBITDA Median US Buyout Multiples levels since 2014 − The increased use of debt was driven by 2H20 back- end loaded lending activity (primarily 4Q20) as 16.0x 12.7x 14.1x 12.2x 12.0x 11.6x 11.5x certainty around the U.S. election and vaccination 11.1x 10.0x 9.8x 12.0x 9.7x expectations increased 9.4x 8.6x 8.3x 8.2x 7.5x 7.8x 5.2x 6.7x 5.7x 5.6x ▪ 8.0x 5.9x As the effects of COVID now begin to diminish, debt 5.4x 4.4x 4.1x 3.7x 4.6x 4.3x 3.8x markets have seemingly recovered, signaling that 3.6x lenders have become increasingly comfortable with 4.0x 4.3x 6.9x 6.5x 6.3x 6.0x 5.9x 5.7x 5.7x 5.7x 5.7x 5.6x 5.3x 4.5x 4.4x macroeconomic and company-specific fundamentals 4.3x 0.0x 3.2x − With increased confidence, lenders are currently looking to provide strong leverage for high-quality assets, particularly ones that have proven their Debt/EBITDA Equity/EBITDA EV/EBITDA stability through the recent market downturn Source: PitchBook ▪ The spread on U.S. high-yield debt has returned to pre- Historical US High Yield Debt Effective Yield COVID levels − 4.22% current effective yield compared with a 12.0% 11.4% 11.38% effective yield on March 23, 2020 (peak of the pandemic) 9.0% ▪ We expect increased activity by lenders in 2021 due to: 6.0% 4.2% − Pent-up demand in M&A activity driven by the impact of COVID 3.0% − Limited Partner agreements and investor
    [Show full text]
  • Moderna Vaccine Day Presentation
    Zika Encoded VLP mRNA(s) RSV CMV + EBV SARS-CoV- RSV-ped 2 Flu hMPV/PIV3 H7N9 Encoded mRNA(s) Ribosome Protein chain(s) First Vaccines Day April 14, 2020 © 2020 M oderna Therapeutics Forward-looking statements and disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning; the impact of the SARS-CoV-2 pandemic on the Company’s clinical trials and operations; the timing and finalization of a dose-confirmation Phase 2 study and planning for a pivotal Phase 3 study for mRNA-1647; the status and outcome of the Phase 1 clinical trial for mRNA-1273 being conducted by NIH; the next steps and ultimate commercial plan for mRNA-1273; the size of the potential market opportunity for mRNA-1273; the size of the potential commercial market for novel vaccines produced by Moderna or others; the potential peak sales for the Company’s wholly-owned vaccines; the probability of success of the Company’s vaccines individually and as a portfolio; and the ability of the Company to accelerate the research and development timeline for any individual product or the platform as a whole. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
    [Show full text]
  • Wyeth Pharmaceuticals Inc., a Subsidiary of Pfizer Inc Mylotarg
    Mylotarg FDA ODAC Briefing Document 11 July 2017 WYETH PHARMACEUTICALS INC., A SUBSIDIARY OF PFIZER INC MYLOTARG (gemtuzumab ozogamicin; PF-05208747) In combination with chemotherapy for the treatment of previously untreated de novo CD33-positive acute myeloid leukemia and as monotherapy for the treatment of CD33-positive acute myeloid leukemia in first relapse FDA ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT (BLA 761060) Meeting Date: 11 July 2017 ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE 090177e18c1aa788\Approved\Approved On: 12-Jun-2017 13:05 (GMT) Page 1 Mylotarg FDA ODAC Briefing Document 11 July 2017 TABLE OF CONTENTS TABLE OF CONTENTS...........................................................................................................2 LIST OF TABLES.....................................................................................................................5 LIST OF FIGURES ...................................................................................................................6 1. EXECUTIVE SUMMARY .................................................................................................7 1.1. Introduction..............................................................................................................7 1.2. Rationale for Mylotarg Dosing Regimens ...............................................................8 1.3. Mylotarg in Patients With Previously Untreated De Novo AML............................9 1.4. Mylotarg in Patients With AML in First Relapse..................................................11
    [Show full text]
  • COVID-19 Treatment and Vaccine Tracker This Document Contains an Aggregation of Publicly Available Information from Validated Sources
    COVID-19 Treatment and Vaccine Tracker This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development. TREATMENTS Current Type of FDA-Approved Clinical Trials for Funding Clinical Trials for Anticipated Next Number Developer/Researcher Stage of Published Results Sources Product - Treatment Indications Other Diseases Sources COVID-19 Steps Timing Development ANTIBODIES PhRMA Begin Phase 1 trials in late Polyclonal hyperimmune Alliance among Takeda, CSL Behring, Wall Street Journal spring. To patients between 1 globulin (H-IG), formerly N/A Biotest AG, Bio Products Laboratory, Pre-clinical Pink Sheet December 2020 and December known at TAK-888 LFB, and Octapharma Press release from the 2021 alliance Biomedical Stat News Advanced MarketWatch Antibodies from mice, Research and Reuters 2 REGN3048-3051, against the N/A Regeneron Pre-clinical Start Phase 1 June 2020 Development Bloomberg News spike protein Authority FierceBiotech (BARDA) FiercePharma Korea Herald Antibodies from recovered 3 N/A Celltrion Pre-clinical Start Phase 1 in July 2020 UPI COVID-19 patients Celltrion press release Super-antibody or antibody 4 cocktail to target potential N/A Celltrion Pre-clinical Celltrion press release mutations of SARS-CoV-2 Antibodies from recovered BioSpace 5 N/A Kamada Pre-clinical COVID-19 patients AbbVie Stat News Antibodies from recovered 6 N/A Vir Biotech/WuXi Biologics/Biogen Pre-clinical Start Phase 1 ~ July 2020 Vir Biotech COVID-19 patients Vir Biotech * Indicates updated or new field This document contains an aggregation of publicly available information from validated sources.
    [Show full text]
  • Eople on the Move Eople on the Move
    eopleeople onon PPthethe movemove Pierre Cloutier Sylvie Denis Gilles Fortin Nicolas Gauvin Bernard Michaud Anna Kratochvil Abbott Abbott Abbott Abbott Abbott Abbott Laboratories Laboratories Laboratories Laboratories Laboratories Laboratories Gary Schmid Alison Shore Eric Bergey Kal Dreisziger Lidia Krupka Abbott Abbott L’Académie- Allard-Johnson Allard-Johnson Laboratories Laboratories Ogilvy Communications Communications (Montreal) (Montreal) Pierre Cloutier, formerly Business Nicolas Gauvin, formerly Senior Alison Shore, formerly Product Unit Manager, Oncology, Product Manager, GI, has been Manager, has been promoted to Pharmaceutical Products Division, promoted to Marketing Manager, GI, Senior Product Manager, Metabolic has been promoted to Director, Pharmaceutical Products Division, at (Meridia), Pharmaceutical Products Customer Relations (Corporate), at Abbott Laboratories. Division, at Abbott Laboratories. Abbott Laboratories. Bernard Michaud, formerly Senior Eric Bergey, formerly International Sylvie Denis, formerly Business Unit Product Manager, Anti-infectives, has OTC Product Manager at World Manager, Cardiovascular & been promoted to Marketing Headquarters of Pharmacia & Metabolic, has been promoted to Manager, Anti-infectives, Upjohn in Sweden and, most Director of Sales, Primary Care, Pharmaceutical Products Division, at recently, Account Supervisor at Jeffrey Pharmaceutical Products Division, at Abbott Laboratories. Simbrow Associates (Montreal), has Abbott Laboratories. been appointed Account Director at Anna Kratochvil,
    [Show full text]
  • Statements Contained in This Release As the Result of New Information Or Future Events Or Developments
    Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant NEW YORK and MAINZ, GERMANY, July 8, 2021 — As part of Pfizer’s and BioNTech’s continued efforts to stay ahead of the virus causing COVID-19 and circulating mutations, the companies are providing an update on their comprehensive booster strategy. Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses. The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA, EMA and other regulatory authorities in the coming weeks. In addition, data from a recent Nature paper demonstrate that immune sera obtained shortly after dose 2 of the primary two dose series of BNT162b2 have strong neutralization titers against the Delta variant (B.1.617.2 lineage) in laboratory tests. The companies anticipate that a third dose will boost those antibody titers even higher, similar to how the third dose performs for the Beta variant (B.1.351). Pfizer and BioNTech are conducting preclinical and clinical tests to confirm this hypothesis. While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant.
    [Show full text]
  • Johnson & Johnson and Pfizer Inc., Analysis of Agreement Containing
    ANALYSIS OF AGREEMENT CONTAINING CONSENT ORDERS TO AID PUBLIC COMMENT In the Matter of Johnson & Johnson and Pfizer Inc. File No. 061-0220, Docket No. C-4180 I. Introduction The Federal Trade Commission (“Commission”) has accepted, subject to final approval, an Agreement Containing Consent Orders (“Consent Agreement”) from Johnson & Johnson (“J&J”) and Pfizer Inc. (“Pfizer”), which is designed to remedy the anticompetitive effects that would otherwise result from J&J’s proposed acquisition of Pfizer Consumer Healthcare. Under the terms of the proposed Consent Agreement, the parties will be required to divest: (1) Pfizer’s Zantac® H-2 blocker business; (2) Pfizer’s Cortizone® hydrocortisone anti-itch business; (3) Pfizer’s Unisom® nighttime sleep-aid business; and (4) J&J’s Balmex® diaper rash treatment business. The proposed Consent Agreement has been placed on the public record for thirty (30) days for receipt of comments by interested persons. Comments received during this period will become part of the public record. After thirty (30) days, the Commission will again review the proposed Consent Agreement and will decide whether it should withdraw from the proposed Consent Agreement, modify it, or make final the Decision and Order (“Order”). Pursuant to a Stock and Asset Purchase Agreement dated June 25, 2006, J&J proposes to acquire certain voting securities and assets comprising Pfizer’s Consumer Healthcare business in a transaction valued at approximately $16.6 billion (“Proposed Acquisition”). The Commission’s complaint alleges that the Proposed Acquisition, if consummated, would violate Section 7 of the Clayton Act, as amended, 15 U.S.C.
    [Show full text]